1
Questioning risk compensation: pre-exposure prophylaxis (PrEP) and sexually transmitted infections among men who have sex with men, capital region of Denmark, 2019 to 2022
Sebastian von Schreeb, Susanne Kriegel Pedersen, Hanne Christensen, Kristina Melbardis Jørgsensen, Lene Holm Harritshøj, Frederik Boetius Hertz, Magnus Glindvad Ahlström, Anne-Mette Lebech, Suzanne Lunding, Lars Nørregaard Nielsen, Jan Gerstoft, Gitte Kronborg and Frederik N Engsig
Eurosurveillance latest updates, 29.03.2024
Tilføjet 29.03.2024
BackgroundPre-exposure prophylaxis (PrEP) effectively prevents HIV, but its association with sexually transmitted infections (STIs) has raised concerns about risk compensation, potentially impacting the expansion of PrEP programmes. AimWe examined the relationship between PrEP and the incidence of chlamydia, gonorrhoea and syphilis. MethodsIn this prospective cohort study, we compared STI rates before and after PrEP initiation among users in the capital region of Denmark (2019–2022), calculating incidence rate ratios adjusted for age and testing frequency (aIRR). To pinpoint when increases began, we plotted weekly STI rates, adjusting the timeline to correspond with PrEP initiation. ResultsThe study included 1,326 PrEP users with a median age of 35 years. The STI incidence rate per 100,000 person-years rose from 35.3 before to 81.2 after PrEP start, with an aIRR of 1.35 (95% CI: 1.18–1.56). Notably, this increase preceded PrEP initiation by 10–20 weeks. Specific aIRR for chlamydia, gonorrhoea and syphilis were 1.23 (95% CI: 1.03–1.48), 1.24 (95% CI: 1.04–1.47) and 1.15 (95% CI: 0.76–1.72), respectively. In subanalyses for anatomical sites aIRR was 1.26 (95% CI: 1.01–1.56) for rectal chlamydia and 0.66 (95% CI: 0.45–0.96) for genital gonorrhoea. ConclusionWe found a 35% increase in STI incidence associated with PrEP use. It started before PrEP initiation, challenging the assumption that PrEP leads to risk compensation. Instead, the data suggest that individuals seek PrEP during periods of heightened sexual risk-taking. Consequently, PrEP programmes should include sexual health consultations, STI testing, treatment and prevention strategies to prevent HIV and improve sexual health.
Læs mere
2
Public health and social measures for health emergencies and pandemics in the EU/EEA: recommendations for strengthening preparedness planning
ECDC
ECDC COVID-19 updates, 20.03.2024
Tilføjet 20.03.2024
This guidance outlines key strategic and operational considerations to inform pandemic preparedness planning round the design and implementation of public health and social measures in community settings in the EU/EEA.
Læs mere
3
AstraZeneca to Invest 650 Million Pounds in UK to Boost Pandemic Preparedness
Medscape Infectious Diseases, 7.03.2024
Tilføjet 7.03.2024
AstraZeneca plans to invest 650 million pounds ($826.80 million) in Britain to boost research, development and manufacturing of vaccines, the government announced on... Reuters Health Information
Læs mere
4
Laboratory Support for influenza and SARS-CoV-2 for Europe: AURORAE
ECDC
ECDC COVID-19 updates, 15.02.2024
Tilføjet 15.02.2024
AURORAE provides laboratory support for surveillance, preparedness and response to COVID-19 and influenza and strengthens the capacity for genomic epidemiology and public health bioinformatics through interdisciplinary training, which is crucial for response during a pandemic or unexpected major public health events.
Læs mere
5
MMWR Supplement: Characteristics Associated with Pre-Exposure Prophylaxis Discussion and Use Among Transgender Women Without HIV Infection - National HIV Behavioral Surveillance Among Transgender Women, Seven Urban Areas, United States, 2019-2020
Morbidity and Mortality Weekly Report (MMWR), 26.01.2024
Tilføjet 26.01.2024
This report examines whether transgender women who report behaviors associated with HIV acquisition were more likely to have had discussions with their clinician about pre-exposure prophylaxis (PrEP) and used PrEP.
Læs mere
6
Long-Acting PrEP in Europe's Fight Against HIV
Medscape Infectious Diseases, 1.12.2023
Tilføjet 1.12.2023
Europe\'s advances in HIV prevention strategies, including PrEP and long-acting retrovirals, bring hope amidst persistent access challenges and disparities. Medscape Medical News
Læs mere
7
Helping Patients Stay Safe From Respiratory Viruses
Medscape Infectious Diseases, 14.11.2023
Tilføjet 14.11.2023
CDC\'s Demetre Daskalakis, MD, MPH, discusses how to prepare for the 2023-2024 fall and winter virus season. CDC Expert Commentary
Læs mere
8
Routine Vaccination Coverage - Worldwide, 2022
Morbidity and Mortality Weekly Report (MMWR), 26.10.2023
Tilføjet 26.10.2023
From 2021 to 2022, global coverage with the first dose of diphtheria-tetanus-pertussis-containing vaccine increased from 86% to 89%, and with the first dose of measles-containing vaccine from 81% to 84%, but neither returned to 2019 prepandemic coverage levels of 90% and 86%, respectively.
Læs mere